NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics

NovoCure Limited - Ordinary Shares (NVCR): $216.28

-1.20 (-0.55%)

POWR Rating

Component Grades














  • Quality is the dimension where NVCR ranks best; there it ranks ahead of 86.89% of US stocks.
  • The strongest trend for NVCR is in Growth, which has been heading down over the past 31 weeks.
  • NVCR ranks lowest in Sentiment; there it ranks in the 5th percentile.

NVCR Stock Summary

  • NVCR's current price/earnings ratio is 1,868.37, which is higher than 99.53% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NVCR is currently 190.59, higher than 97.99% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 250.72%, NovoCure Ltd's debt growth rate surpasses 95.87% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to NovoCure Ltd, a group of peers worth examining would be AMRN, SU, JJSF, FMX, and ANGI.
  • To dig deeper into the stock's financial statements, go to NVCR's page on browse-edgar?action=getcompany&CIK=0001645113.

NVCR Price Target

For more insight on analysts targets of NVCR, see our NVCR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $191.71 Average Broker Recommendation 2 (Hold)

NVCR Stock Price Chart Interactive Chart >

Price chart for NVCR

NVCR Price/Volume Stats

Current price $216.28 52-week high $220.48
Prev. close $217.48 52-week low $55.40
Day low $212.56 Volume 374,600
Day high $218.48 Avg. volume 887,277
50-day MA $187.48 Dividend yield N/A
200-day MA $150.83 Market Cap 22.37B

NovoCure Limited - Ordinary Shares (NVCR) Company Bio

NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.

NVCR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$216.28$23049.52 12644%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for NovoCure Ltd. To summarize, we found that NovoCure Ltd ranked in the 98th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. The most interesting components of our discounted cash flow analysis for NovoCure Ltd ended up being:

  • The company's compound free cash flow growth rate over the past 1.99 years comes in at 4.19%; that's greater than 97.05% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately just 13.12% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • As a business, NovoCure Ltd experienced a tax rate of about 22% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 88.14% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

VRTX, HROW, THC, AMRX, and FVE can be thought of as valuation peers to NVCR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

NVCR Latest News Stream

Event/Time News Detail
Loading, please wait...

NVCR Latest Social Stream

Loading social stream, please wait...

View Full NVCR Social Stream

Latest NVCR News From Around the Web

Below are the latest news stories about NovoCure Ltd that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

NovoCure: The Future Of Cancer Treatment

sakkmesterke/iStock via Getty Images Never promote someone who hasn’t made some bad mistakes, because if you do, you are promoting someone who has never done anything. - Phillip Fisher (Warren Buffett's mentor) It's a thing of beauty when you discover a bio-stock delivering a breakthrough therapy. Such growth equity usually...

BioSci Capital Partners on Seeking Alpha | June 12, 2021

Dow Jones Futures: Apple Vs. Microsoft Vs. Google; How To Be A Big Stock Market Winner

Apple, Microsoft and Google are in bases, but which is the most promising? To be a big stock market winner, be a small loser.

Yahoo | June 12, 2021

NovoCure Ltd (NVCR): Price Down $-3.85 (-1.77)% Over Past Day, Down $-1.81 (-0.84)% Over Past Hour

If you''re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 20 hour timeframe. The post NovoCure Ltd (NVCR): Price Down $-3.85 (-1.77)% Over Past Day, Down $-1.81 (-0.84)% Over Past Hour appeared first on ETF Daily News .

ETF Daily News | June 11, 2021

3 Unstoppable Stocks That Can Leave Dogecoin in the Dust

Dogecoin (CRYPTO: DOGE) has been all over the news in 2021, and for good reason. Dogecoin has no significant competitive advantage over other cryptocurrencies -- be it transaction fees or payment speeds. Retail investors should stay away from such speculative investments to safeguard their portfolios from extreme ups and downs.

Yahoo | June 5, 2021

We Think Shareholders Will Probably Be Generous With NovoCure Limited's (NASDAQ:NVCR) CEO Compensation

It would be hard to discount the role that CEO Asaf Danziger has played in delivering the impressive results at...

Yahoo | June 2, 2021

Read More 'NVCR' Stories Here

NVCR Price Returns

1-mo 20.64%
3-mo 51.20%
6-mo 37.64%
1-year 239.21%
3-year 599.94%
5-year 1,910.04%
YTD 24.99%
2020 105.34%
2019 151.70%
2018 65.74%
2017 157.32%
2016 -64.89%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8984 seconds.